Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)

The Scientist

The Scientist
19 Followers
1 Following
Send Message
View The Scientist's StockTalks BY TICKER:
  • The Scientist
    Nice move for $CYTK. Still more to come. At least $10/share.
    9 hours ago
    Reply
      • The Scientist
        Nice move today and a vote of confidence from $AMGN. $CYTK current move has a long way to go.
        Jun 12, 9:48 PM
        Reply
          • The Scientist
            RS is almost never a good thing for stocks. As long as Omecamtiv and Tirasemtiv trials go well, $CYTK will be ok
            Apr 11, 8:29 PM
            Reply
              • The Scientist
                Even if $CYTK does RS, not too bad. Most important - both of their drugs succeed in trials. If drugs succeed, $CYTK will do just fine.
                Apr 3, 1:25 PM
                Reply (1)
                • Michael Webb: Purpose of reverse split: another round of dilutive stock offerings to hedge their bets on an Amgen pullout. That's a problem.
                  Apr 11, 3:37 PM
                  • The Scientist
                    Tirasemtiv P2b trial for ALS really a P3! $CYTK stated many times they will go to FDA for drug approval if + results.
                    Mar 25, 1:12 PM
                    Reply (1)
                    • Michael Webb: This is my riskiest biotech investment. I hope it goes well as I continue to purchase shares. You can feel the apprehension. Go Cyto!
                      Apr 1, 5:48 AM
                      • The Scientist
                        Thank you very much Mr. Smith for the great article on $CYTK. Given its pipeline and $AMGN partnership, still ridiculously undervalued!
                        Mar 25, 12:59 PM
                        Reply
                          • The Scientist
                            As I said before, $MDVN is a $DNDN killer.
                            Mar 6, 12:30 PM
                            Reply
                              • The Scientist
                                $CYTK still ridiculously undervalued. Current levels give no real value to pipeline. Near total failure priced in.
                                Mar 3, 9:21 PM
                                Reply (3)
                              • View all 3 replies
                                • The Scientist: Wall St totally ignoring CYTK. Exact same thing happened with SRPT. SRPT was way below $1 for a long time before getting noticed.
                                  Mar 19, 4:28 AM
                                • Michael Webb: Buying shares today. Fabulous presentation at the 25th annual Roth Conference you can find here: http://bit.ly/137bF4l
                                  Mar 19, 5:09 AM
                                  • The Scientist
                                    No other heart failure drug can do what $CYTK Omecamtiv can: raise SV, lower BP/HR. If proven safe, a true miracle drug. Gives HF pts hope.
                                    Mar 3, 9:17 PM
                                    Reply
                                      • The Scientist
                                        Looking forward to $CYTK presentation at American College of Cardiology meeting next weekend. Omecamtiv will transform heart failure tx
                                        Mar 1, 12:00 PM
                                        Reply
                                          • The Scientist
                                            Article on SA talks about buyer exhaustion for $CYTK. Nice call. $CYTK has just started this rally. Drugs with $multibillion potential.
                                            Jan 29, 11:50 AM
                                            Reply
                                              • The Scientist
                                                If $CYTK can get above the $3 level, will then start to see some real buying action from big institutional investors.
                                                Jan 24, 9:06 PM
                                                Reply (1)
                                                • The Scientist: Vanguard, Fidelity, Deutsche Bank and T Rowe Price already on board as major shareholders.
                                                  Jan 24, 9:09 PM
                                                  • The Scientist
                                                    $CYTK having a nice high volume rally to start the year.
                                                    Jan 24, 9:05 PM
                                                    Reply
                                                      • The Scientist
                                                        Wall Street finally giving $CYTK the attention it deserves. No other biotech has anything close to Omecamtiv and Tirasemtiv in development.
                                                        Jan 8, 12:09 PM
                                                        Reply
                                                          • The Scientist
                                                            Some on Wall St, like Piper, see the value of $CYTK. Given the broad market potential for both ome and tira, $CYTK best value in biotech
                                                            Jan 3, 6:32 PM
                                                            Reply
                                                              • The Scientist
                                                                With $BIIB failure, $CYTK has the most promising ALS drug in development. BTW, it also has the most promising HF drug in development.
                                                                Jan 3, 1:12 PM
                                                                Reply
                                                                  • The Scientist
                                                                    $CYTK to present at the Am College Cardio meeting 3/12. Could cause large price movement. Omecamtiv a potential wonder drug for HF
                                                                    12/22/12
                                                                    Reply
                                                                      • The Scientist
                                                                        Boxed warning a total shock for $ARIA. Arterial thrombosis is quite rare but extremely dangerous. 8% is a high number.
                                                                        12/14/12
                                                                        Reply
                                                                          • The Scientist
                                                                            $CYTK stock price makes absolutely NO sense. Omecamtiv and Tirasemtiv both potential revolutionary/blockbuster drugs. $AMGN partnered.
                                                                            12/13/12
                                                                            Reply
                                                                              • The Scientist
                                                                                $ONCY potential is huge. Reolysin can also be used for many other cancer types. Following: $CYCC $CYTK $ONCY $SNTA $SRPT $YMI
                                                                                12/13/12
                                                                                Reply